RSV InfectionPhase 1NCT03755778
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
A Phase 1 study testing EDP-938, Itraconazole and Rifampin in people with RSV Infection, run by Enanta Pharmaceuticals, Inc at 1 site in United States.
Trial summary
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- RSV Infection
- What is being tested?
- EDP-938, Itraconazole and Rifampin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Nov 2018to 27 Jan 2019
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- An informed consent document signed and dated by the subject.
- Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.
- Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg
- Female subjects of childbearing potential must agree to use two effective methods of contraception from the date of Screening until 90 days after the last dose of EDP 938.
Who cannot join
- Clinically relevant evidence or history of illness or disease.
- For Part 3 subjects, the following cardiovascular abnormalities:
- QRS duration >110 ms
- Incomplete right bundle branch block or any complete bundle branch block
- Heart rate <40 or >90 beats per minute (per vital sign capture while rested)
- History of unexplained syncope, structural heart disease, or clinically significant arrhythmias
Show all 16Show fewer
- Personal or family history of long QT syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or Brugada syndrome
- PR interval >220 ms or any 2nd or 3rd degree AV block
- Ventricular pre-excitation
- Pregnant or nursing females.
- History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
- A positive urine drug screen at Screening or Day -1.
- Current tobacco smokers or use of tobacco within 3 months prior to Screening.
- Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
- History of regular alcohol consumption.
- Participation in a clinical trial within 30 days prior to the first dose of study drug.
Trial locations and contacts
1 site in 1 country.
United States1 site
Pharmaceutical Research Associates, Inc.,
Lenexa, Kansas, 66219
About this study
Official title: A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
- Conditions
- RSV Infection
- Being tested
- EDP-938, Itraconazole, Rifampin, Quinidine
- Keywords
- drug-drug interaction
- Medical subject headings
- Respiratory Syncytial Virus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EDP-938Drug
Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
EDP-938Drug
Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
EDP-938Drug
Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
ItraconazoleDrug
Subjects will receive itraconazole once daily from Day 5 to Day 18
RifampinDrug
Subjects will receive rifampin once daily from Day 5 to Day 16
QuinidineDrug
Subjects will receive quinidine once daily from Day 5 to Day 12
| Study group | Role | What they receive |
|---|---|---|
| EDP-938 and itraconazole interaction (Part 1) | Experimental | Not described Receives: Drug: EDP-938; Drug: Itraconazole |
| EDP-938 and rifampin interaction (Part 2) | Experimental | Not described Receives: Drug: EDP-938; Drug: Rifampin |
| EDP-938 and quinidine interaction (Part 3) | Experimental | Not described Receives: Drug: EDP-938; Drug: Quinidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax of EDP-938 with and without coadministration with itraconazole
Measured: Up to 19 days
AUC of EDP-938 with and without coadministration with itraconazole
Measured: Up to 19 days
Cmax of EDP-938 with and without coadministration with rifampin
Measured: Up to 17 days
AUC of EDP-938 with and without coadministration with rifampin
Measured: Up to 17 days
Cmax of EDP-938 with and without coadministration with quinidine
Measured: Up to 13 days
AUC of EDP-938 with and without coadministration with quinidine
Measured: Up to 13 days
Secondary outcomes (1)
Safety measured by adverse events
Measured: Up to 25 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2018
- Study start29 Nov 2018
- Primary completion21 Jan 2019
- Study completion27 Jan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RSV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- 3-Part Single Group study
- Masking
- None (open label)
- Enrolment
- 72 participants (actual)
Sponsor and investigators
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Pharmaceutical Research Associates
- Responsible party
- Sponsor
- Investigators
- Enanta Pharmaceuticals, Study director, Enanta Pharmaceuticals, Inc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03755778
- Sponsor's protocol ID
- EDP 938-003
- Status last verified
- Oct 2018
- First submitted
- 26 Nov 2018
- Last updated
- 14 Jun 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jun 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
- ClinicalTrials.gov ID
- NCT03755778
- Acronym / sponsor ID
- EDP 938-003
- Conditions
- RSV Infection
- Keywords
- drug-drug interaction
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 72 participants (actual)
- Lead sponsor
- Enanta Pharmaceuticals, IncIndustry (pharma, biotech, devices)
- Collaborators
- Pharmaceutical Research Associates
- Study start
- 29 Nov 2018 (actual)
- Primary completion
- 21 Jan 2019 (actual)
- Study completion
- 27 Jan 2019 (actual)
- First posted
- 28 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- 3-Part Single Group study
| Arm | Type | Receives |
|---|---|---|
| EDP-938 and itraconazole interaction (Part 1) | Experimental | Drug: EDP-938, Drug: Itraconazole |
| EDP-938 and rifampin interaction (Part 2) | Experimental | Drug: EDP-938, Drug: Rifampin |
| EDP-938 and quinidine interaction (Part 3) | Experimental | Drug: EDP-938, Drug: Quinidine |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- An informed consent document signed and dated by the subject.
- Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.
- Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg
- Female subjects of childbearing potential must agree to use two effective methods of contraception from the date of Screening until 90 days after the last dose of EDP 938.
Key exclusion criteria (16 listed)
- Clinically relevant evidence or history of illness or disease.
- For Part 3 subjects, the following cardiovascular abnormalities:
- Pregnant or nursing females.
- History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
- A positive urine drug screen at Screening or Day -1.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EDP-938Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1) | Drug | EDP-938 and itraconazole interaction (Part 1) |
| EDP-938Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2) | Drug | EDP-938 and rifampin interaction (Part 2) |
| EDP-938Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3) | Drug | EDP-938 and quinidine interaction (Part 3) |
| ItraconazoleSubjects will receive itraconazole once daily from Day 5 to Day 18 | Drug | EDP-938 and itraconazole interaction (Part 1) |
| RifampinSubjects will receive rifampin once daily from Day 5 to Day 16 | Drug | EDP-938 and rifampin interaction (Part 2) |
| QuinidineSubjects will receive quinidine once daily from Day 5 to Day 12 | Drug | EDP-938 and quinidine interaction (Part 3) |
Primary outcome
Cmax of EDP-938 with and without coadministration with itraconazole
Time frame: Up to 19 days
AUC of EDP-938 with and without coadministration with itraconazole
Time frame: Up to 19 days
Cmax of EDP-938 with and without coadministration with rifampin
Time frame: Up to 17 days
AUC of EDP-938 with and without coadministration with rifampin
Time frame: Up to 17 days
Cmax of EDP-938 with and without coadministration with quinidine
Time frame: Up to 13 days
AUC of EDP-938 with and without coadministration with quinidine
Time frame: Up to 13 days
1 secondary outcome
Safety measured by adverse events
Time frame: Up to 25 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jun 2019.
Related trials for RSV Infection
Active, not recruitingPhase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Respiratory Syncytial Virus Infections
Active, not recruitingPhase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Respiratory Syncytial Virus (RSV), Infectious Disease
Not yet recruitingPhase 3
A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection
RecruitingObservational study
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
COVID-19, SARS-CoV-2 Infection, RSV
RecruitingPhase 2/3
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
RSV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Enanta Pharmaceuticals study director
Enanta Pharmaceuticals, Inc
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing EDP-938, Itraconazole and Rifampin in people with RSV Infection, run by Enanta Pharmaceuticals, Inc at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax of EDP-938 with and without coadministration with itraconazole (time frame: Up to 19 days). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2019.